Swiss multinationals step up US lobbying

Swiss multinational corporations in the United States have ramped up efforts to influence American policy making, spending nearly CHF22 million ($23.3 million) on lobbying last year.  From tax reform to repealing and replacing the Affordable Care Act (Obamacare), Swiss multinationals – especially those in the pharmaceutical and financial sectors – have left nothing to chance.  While it is not unusual for multinationals, via their US-based subsidiaries, to engage in lobbying, the amounts of money spent by Swiss firms on lobbying in 2017 rose markedly compared with previous years, according to data from US transparency organisation Center for Responsive Politics (CRP).  Spending by pharmaceutical manufacturer Novartis on lobbying rose from CHF6.4 million in 2016 to CHF8.11 million in 2017. On a smaller but equally ambitious scale, industrial digital technology company ABB Group doubled its spending on lobbying to CHF500,000.  According to the CRP, the lobbying spend of these ...

 
More Headlines

Follow worldbiztoday on Twitter

US Stocks